You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME/CE

Statins Reduce CV Events in People With Abnormal Liver Function Tests

  • Authors: News Author: Michael O’Riordan
    CME Author: Laurie Barclay, MD
  • CME/CE Released: 12/1/2010
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 12/1/2011
Start Activity


Target Audience and Goal Statement

This article is intended for primary care clinicians, cardiologists, hepatologists, and other specialists caring for patients with abnormal liver test results in whom statins could be indicated.

The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  1. Describe the effect of statin therapy on liver tests in patients with moderately abnormal liver test results, based on a post hoc analysis.
  2. Describe the effect of statin therapy on cardiovascular events in patients with moderately abnormal liver test results, based on a post hoc analysis.


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Michael O'Riordan

    Michael O'Riordan is a journalist for Medscape. Before becoming a journalist for theheart.org, now part of the WebMD Professional Network, he worked for WebMD Canada. Michael studied at Queen's University in Kingston and the University of Toronto and has a master's degree in journalism from the University of British Columbia, where he specialized in medical reporting. He can be contacted at [email protected]

    Disclosures

    Disclosure: Michael O'Riordan has disclosed no relevant financial relationships.

Editor(s)

  • Brande Nicole Martin

    CME Clinical Editor, Medscape, LLC

    Disclosures

    Disclosure: Brande Nicole Martin has disclosed no relevant financial relationships.

CME Author(s)

  • Laurie Barclay, MD

    Freelance writer and reviewer, Medscape, LLC

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

CME Reviewer(s)

  • Sarah Fleischman

    CME Program Manager, Medscape, LLC

    Disclosures

    Disclosure: Sarah Fleischman has disclosed no relevant financial relationships.

Nurse Planner

  • Laurie E. Scudder, DNP, NP

    Nurse Planner, Continuing Professional Education Department, Medscape, LLC; Clinical Assistant Professor, School of Nursing and Allied Health, George Washington University, Washington, DC

    Disclosures

    Disclosure: Laurie E. Scudder, DNP, NP, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should only claim credit commensurate with the extent of their participation in the activity.

    This activity, MedscapeCME Clinical Briefs has been reviewed and is acceptable for up to 300 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins September 1, 2010. Term of approval is for 1 year from this date. Each issue is approved for .25 Prescribed credits. Credit may be claimed for 1 year from the date of this issue.

    Note: Total credit is subject to change based on topic selection and article length.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    AAFP Accreditation Questions

    Contact This Provider

    For Nurses

  • Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

    Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; 0.5 contact hours are in the area of pharmacology.

    Accreditation of this program does not imply endorsement by either Medscape, LLC or ANCC.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number 0461-0000-10-284-H04-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. MedscapeCME encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME/CE

Statins Reduce CV Events in People With Abnormal Liver Function Tests

Authors: News Author: Michael O’Riordan CME Author: Laurie Barclay, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME/CE Released: 12/1/2010

Valid for credit through: 12/1/2011

processing....

December 1, 2010 — A post hoc analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study suggests that physicians should not let mildly to moderately abnormal liver test results stop them from using a statin in patients with coronary heart disease [1]. Statin therapy is not only safe in these patients, report investigators, but it significantly reduces the risk of cardiovascular events and improves liver-function tests.

"The data in the last few years have shown that these patients with elevated liver-function tests are at a greater risk of vascular events, and we wanted to see if that were true," senior investigator Dr Dimitri Mikhailidis (University College London Medical School, UK) told heartwire . "Indeed, there was an increased risk among these patients, and we found that they also had a bigger benefit and that they improved their liver function with a statin. Also, we found the opposite in patients not treated with a statin, that their liver-function tests tended to become more abnormal over time, although this probably reflects them getting fatter over three years in the study."

In an editorial accompanying the study [2], Dr Ted Bader (University of Oklahoma Health Sciences Center, Oklahoma City) called the analysis "groundbreaking." He said it is unknown how many patients are denied statins because of preexisting changes in liver-function tests or how many have the lipid-lowering drugs stopped after elevations in liver-enzyme concentrations, but he suspects that 10% to 30% of patients who need statins might fall into this category.

"This large group represents a substantial source of cardiovascular disease, which is not being prevented," writes Bader. "Further harm ensues from the cost of monitoring with liver-function tests. One estimate conservatively placed the cost of monitoring statins with liver-function tests at US $10 billion per year."

The results of the study and editorial are published online November 24, 2010 in the Lancet.

The GREACE Trial

To heartwire , Mikhailidis said that nonalcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver-function tests and that the severity of NAFLD increases in patients with higher body-mass index and triglyceride concentrations, as well as in patients with diabetes, hypertension, and insulin resistance. These patients also have a higher risk of all-cause mortality, mainly caused by an increased risk of cardiovascular events. Previously published data, however, as well as their own experience, suggested that statins were safe in patients with NAFLD.

Despite this, physicians can practice medicine defensively, said Mikhailidis, and might be reluctant to prescribe statins to patients with elevated liver enzymes at baseline. The purpose of the post hoc analysis was to assess the risk/benefit ratio in GREACE patients treated with a statin who had moderately abnormal liver tests, defined as serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) less than three times the upper limit of normal (<3x ULN).

In total, 227 patients were treated with statins, typically atorvastatin (Lipitor, Pfizer), over the three-year study. Statin therapy reduced baseline low-density lipoprotein cholesterol levels from 170 mg/dL to 95 mg/dL, as well as significantly reduced total cholesterol and triglyceride levels. Measures of liver function were also significantly improved, with ALT and AST concentrations reduced 35% and 47%, respectively. In a control cohort of 210 patients not treated with statins, lipid levels were unchanged, while liver-function tests showed increased ALT and AST concentrations.

In terms of cardiovascular morbidity, fewer patients with impaired liver-function tests treated with a statin had a cardiovascular event--nonfatal MI, revascularization, unstable angina, and congestive heart failure, as well as stroke and all-cause mortality--when compared with impaired liver-function-test patients who did not receive a statin. After three years, the event rate was 9.7%, or 3.2 events per 100-patient years, among the statin-treated patients, compared with 30.0%, or 10.0 cardiovascular events per 100-patient years, among those not treated with a statin.

Speaking with heartwire , Mikhailidis said the relative benefit among patients with mildly to moderately elevated liver-function tests was greater than that observed among patients with normal liver-function tests at baseline. For example, in those with normal ALT and AST concentrations at baseline, the relative reduction in cardiovascular events was 39%, compared with a 68% relative reduction in cardiovascular risk among those with mild to moderate elevations in liver enzymes.

Despite the results, Mikhailidis said there are important limitations to the study. "You have to remember, the numbers are small, with just 200 patients or so in each arm, and the duration is short, at three years," he said. "Most important of all, it's a post hoc analysis. You have to be very, very careful in post hoc analyses that you don't go about finding things and then proclaiming something huge. All of these factors are a considerable disadvantage, or weakness, in our conclusions."

Still, Mikhailidis told heartwire the data confirm the elevated risk of cardiovascular events among patients with NAFLD and hopes the work triggers similar post hoc analyses of the larger statin trials.

Statin-Induced Hepatotoxicity a Myth

In his editorial, Bader said that statin-induced liver toxicity is a myth, one that is fueled by the language in the package insert of the drugs. Large studies have shown no difference in the frequency or degree of ALT increases between treatment and placebo groups, and there are no reports of chronic carriers of drug-induced liver damage from statins.

Bader stressed that an elevation in ALT does not represent a disease state, yet many US physicians are reluctant to prescribe a statin to patients with ALT increases even 1.5x ULN. The finding of improved liver function among the statin-treated patients confirms studies performed in hepatitis-C patients treated with statins, another group in whom doctors are reluctant to prescribe the lipid-lowering drugs, writes Bader.

The authors report no conflicts of interest. Bader reports a patent application with the University of Oklahoma for the use of statins in patients with viral hepatitis.

References

  1. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A post hoc analysis. Lancet 2010; DOI:10.1016/S0140-6736(10)61272-X. Available at: http://www.thelancet.com.
  2. Bader T. Liver tests are irrelevant when prescribing statins. Lancet 2010; DOI:10.1016/S0140-6736(10)61272-X. Available at: http://www.thelancet.com.

Additional Resource
The National Cholesterol Education Program provides ATP III Guidelines At-A-Glance Quick Desk Reference as a downloadable document.

Clinical Context

By inhibiting hepatic production of cholesterol, statin treatment helps reduce the risk for cardiovascular events including myocardial infarction and stroke. Rarely, statin use may cause the adverse effect of increased levels of liver enzymes or serum transaminases such as ALT. Although statins have not been linked to liver injury, a survey showed that half of US academic physicians would be reluctant to give a statin to a patient with an ALT level of more than 1.5 times ULN and that 10% to 30% of patients who could benefit from statins would be denied this treatment.

NAFLD, which affects up to one third of adults in the United States, Europe, and Japan, is the most common cause of high ALT levels. The safety and efficacy of long-term statin treatment is unclear in patients with NAFLD, who often have high cholesterol levels and an increased risk for cardiovascular disease.

Study Highlights

  • This was a post hoc analysis of the study population from GREACE, a prospective, intent-to-treat study performed at the Hippokration University Hospital in Thessaloniki, Greece.
  • With use of a computer-generated randomization list, 1600 patients with coronary heart disease were assigned to receive a statin or usual care, which could include statins.
  • At baseline, participants were younger than 75 years, with serum concentrations of low-density lipoprotein cholesterol at more than 2.6 mmol/L and triglyceride levels at less than 4.5 mmol/L.
  • The goal of this analysis was to determine whether long-term (3-year) statin therapy is safe and effective for patients with moderately abnormal liver test results, defined as serum ALT or AST concentrations at less than 3 times ULN.
  • The main endpoint of the post hoc analysis was risk reduction for first recurrent cardiovascular event in patients who had moderately abnormal liver test results and who were treated with statins vs those who did not receive statins.
  • Patients with alcohol-related liver disease and liver diseases other than NAFLD were excluded.
  • Risk reduction for these patients was compared vs that for patients with normal liver test results who were treated or not treated with a statin.
  • Of 437 patients with moderately abnormal baseline liver test results, possibly because of NAFLD, all 227 who were treated with a statin had substantial improvement in liver test results (P < .0001).
  • The statin used in most of these patients was atorvastatin 24 mg per day.
  • In the 210 patients who did not receive statin treatment, liver enzyme concentrations increased further.
  • There were 22 cardiovascular events among 227 patients with abnormal liver test results who received a statin (10%; 3.2 events per 100 patient-years) vs 63 among 210 patients with abnormal liver test results who did not receive a statin (30%; 10.0 events per 100 patient-years; 68% relative risk reduction, P < .0001).
  • The reduction in cardiovascular disease in patients receiving a statin was greater (P = .0074) than it was in patients with normal liver test results (90 [14%] events in 653 patients receiving a statin [4.6 per 100 patient-years] vs 117 [23%] in 510 patients not receiving a statin [7·6 per 100 patient-years]; 39% relative risk reduction, P < .0001).
  • Of 880 participants who received a statin, 7 (< 1%) discontinued statin treatment because of liver-related adverse effects (transaminase concentrations > 3 times ULN).
  • On the basis of these findings, the investigators concluded that for patients with mild to moderately abnormal liver test results potentially attributable to NAFLD, statin treatment is safe and can improve liver test results and reduce cardiovascular morbidity risk.
  • Long-term (3-year) statin treatment has a significant positive benefit-to-risk ratio in these patients.
  • Limitations of this study include those inherent in a post hoc analysis; and small number of patients with possible NAFLD, preventing use of backward stepwise regression analysis to show the exact reduction in cardiovascular events per international unit per liter reduction in liver test results.

Clinical Implications

  • In a post hoc analysis from GREACE, all patients with abnormal increases in AST or ALT concentrations of up to 3 times ULN who were given a statin had a significant improvement in liver test results at 3-year follow-up, whereas patients with abnormal liver test results who did not receive a statin had a further increase in liver enzyme concentrations during follow-up.
  • In a post hoc analysis from GREACE, statin treatment was associated with a significant 68% decrease in the risk for cardiovascular events in patients with abnormal liver test results, which was greater than the statin-related relative risk reduction in patients with normal liver test results.

CME Test

  • Print